$4.18
+6.1%Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
WHWK • NASDAQ
| Whitehawk Therapeutics Inc Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-20.6M | -63.7M | -65.8M | -60.5M | -110.1M | -3.5M | -12.3M | |
0.0 | 193K | 169K | 159K | 105K | 9K | 6K | |
0.0 | 10.8M | 12M | 9.6M | 2.1M | 139K | 106.1K | |
-78.8M | -10.6M | -2.7M | 6.1M | 81.5M | 2.2M | 3.4M | |
1.9M | 3.7M | -3.3M | -5M | 4M | -11.6M | 1.1M | |
-97.4M | -59.6M | -59.7M | -49.6M | -22.4M | -12.7M | -7.6M | |
INVESTING ACTIVITIES | |||||||
-552K | -1.7M | -4M | -444K | -46K | (0.0) | -35.7K | |
(101.3M) | (0.0) | (0.0) | (0.0) | (25.2M) | (0.0) | (0.0) | |
-148.7M | -36.5M | -64.4M | -145.2M | (0.0) | (0.0) | (0.0) | |
59.8M | 63.3M | 151.6M | 12.8M | 0.0 | 0.0 | 0.0 | |
(11.9M) | (25.2M) | (83.2M) | -132.9M | (25.2M) | (0.0) | -35.7K | |
FINANCING ACTIVITIES | |||||||
100M | 130K | 0.0 | 72.5M | 155M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2M | 8.1M | |
(0.0) | (0.0) | (0.0) | (0.0) | -4.4M | (0.0) | (0.0) | |
-5.6M | 0.0 | 326K | 120K | -8.8M | 0.0 | 0.0 | |
94.4M | 130K | 326K | 72.6M | 141.8M | 1.2M | 8.1M | |
CASH FLOW SUMMARY | |||||||
64K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
8.9M | -34.2M | 23.9M | -109.9M | 144.5M | -11.5M | 16M | |
28.7M | 63M | 39.1M | 149M | 4.5M | 16M | 0.0 | |
37.6M | 28.7M | 63M | 39.1M | 149M | 4.5M | 16M | |
-98M | -61.2M | -63.6M | -50.1M | -22.5M | -12.7M | -7.6M |
WHWK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
S-3 S-3 N/A | May 29, 2026 | May 29, 2026 | ||
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Continue your WHWK research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.